AML-M3; acute promyelocytic leukemia

From Aaushi
Jump to navigation Jump to search

Epidemiology

2-3% of AML

Pathology

Genetics

Clinical manifestations

Laboratory

Management

More general terms

Additional terms

References

  1. Cotran et al Robbins Pathologic Basis of Disease, W.B. Saunders Co, Philadelphia, PA 1989 pg 726
  2. 2.0 2.1 2.2 2.3 2.4 2.5 Medical Knowledge Self Assessment Program (MKSAP) 11, 16, 17, 18, 19. American College of Physicians, Philadelphia 1998, 2012, 2015, 2018, 2022
  3. 3.0 3.1 Powell BL, Moser B, Stock W, Gallagher RE et al Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010 Nov 11;116(19):3751-7. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20705755
  4. 4.0 4.1 Lo-Coco F, Avvisati G, Vignetti M et al Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013 Jul 11;369(2):111-21. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23841729
  5. 5.0 5.1 Altman JK, Rademaker A, Cull E et al Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res. 2013 Sep;37(9):1004-9. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23768930

Patient information

acute promyelocytic leukemia patient information